[DOI] [PubMed] [Google Scholar] 46.Ahrn B., Atkin S.L., Charpentier G., Warren M.L., Wilding J., Birch S., Holst A.G., Leiter L.A
While there is some evidence to suggest that GLP-1 agonists may have health benefits beyond their approved use for type 2 diabetes and obesity, non-diabetics should not take these medications without a prescription and guidance from a healthcare professional
It reports cases of fraudulent compounded drugs, dosing concerns causing hospitalizations, and illegal online sales of drugs
EU/UK GMP Annex 13 (Investigational Medicinal Products)
The hope is that this dual approach might lead to: Enhanced Weight Loss: Beyond Retatrutide's already impressive results, MOTS-c might further optimize fat burning and metabolic adaptation
Another key driver is the diversification of therapeutic area, i.e., obesity and management of cardio metabolic risk to expand market opportunity